SUNNYVALE, Calif.--(BUSINESS WIRE)--The Parkinson’s Institute and Clinical Center and Denali Therapeutics today announced a partnership to explore new clinical endpoints for studies in patients with Parkinson’s Disease (PD).
The Institute and Denali aim to support the development of new PD therapeutics by better understanding the potential of new endpoints for clinical studies. Known clinical endpoints for PD can be affected by current standard treatments which, in turn, may confound the measurement of new therapeutics’ impact.
The agreement brings together the unique expertise of the Institute and its broad patient experience with Denali as it continues the development of its LRRK2 inhibitor clinical program for Parkinson’s Disease.
“This collaboration will allow us to explore new clinical endpoints that may help determine whether therapeutics like Denali’s LRRK2 inhibitors have a measurable effect on Parkinson’s patients,” said Chief Executive Officer, Parkinson’s Institute and Clinical Center, Carrolee Barlow, M.D., Ph.D.
“We are very enthusiastic about partnering with the Parkinson’s Institute, which has done so much to support and foster the development of new approaches to drug development. Having demonstrated our lead LRRK2 inhibitor in the clinic can reduce LRRK2 kinase activity, we are looking forward to exploring the potential of new endpoints for clinical studies in patients,” said Denali Chief Medical Officer and Head of Development, Carole Ho, M.D.
Today’s announcement opens the door to potential future collaborations based on the outcome of the exploration into new endpoints.
About the Parkinson’s Institute and Clinical Center:
The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, basic science research, and clinical research in one integrated model. Our unique freestanding organization directly connects research to patient care – from the "bench to bedside." For 30 years, our team of epidemiologists, physicians, scientists, and therapists, have been at the forefront of every clinical and scientific discovery in the field of Parkinson’s research.
Since our inception, patients have come from 38 states and many foreign countries for their care. We have managed more than 135 clinical research trials, medically evaluating more than 95 different drugs and therapies for Parkinson’s. The result: our Institute has been directly involved in bringing every Parkinson’s drug currently available to the market. The Institute is at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson's.
For more information visit www.thepi.org or call (408) 734-2800.